Global Institute Of Stem Cell Therapy And Research

Category

Giostar News

Ref: EMP_2016_108
Title: Down-regulation of epithelial membrane protein-1 is associated with HNSCC cell proliferation
Journal: Experimental and Molecular Pathology
Corresponding Author: Zezhang Tao
Co-authors: Yang Xiling, Wang Lei, Hu Zhangwei, Xu Yong, Zheng Anyuan, Li Fen, Xiao Bokui, Chen Chen

Dear Dr Srivastava,

I would like to invite you to review the above-referenced manuscript. To maintain our journal’s high standards we need the best reviewers, and given your expertise in this area I would greatly appreciate your contribution.

I kindly ask you to give this review invitation the same consideration that you would want one of your own manuscripts to receive. Please find the abstract of the manuscript at the end of this email.

If you are willing to review this manuscript, please click on the link below:

Please also note that authors have been invited to convert their supplementary material into a Data in Brief article (a data description article). You may notice this change alongside the revised manuscript. You do not need to review this, but may need to look at the files in order to confirm that any supporting information you requested is present there.

I look forward to receiving your response.

Kind regards,

Julius Cruse
Editor-in-Chief
Experimental and Molecular Pathology

Abstract:

To investigate epithelial membrane protein-1 (EMP1) gene function in Head and Neck Squamous Cell Carcinoma (HNSCC) tumorigenesis and development. We first used GEO dataset to analyze the EMP1 gene expression in HNSCC. Second, we investigated the EMP1 protein expression in tissue microassay to analyze the relationship between EMP1 protein expression and TNM stage. Third, the co-expression genes data of EMP1 were extracted from Cancer Cell Line Encyclopedia database(CCLE database) , and their correlation were analyzed in The Cancer Genome Atlas HNSCC database(TCGA HNSCC database). Next, the GO (Gene Ontology Analysis) and KEGG Pathway enrichment analysis were carried out. Finally, we overexpressed the EMP1 in HNSCC cell line Cal-27, protein expression were analyzed by Western blot respectively as well as cell viability and migration were evaluated by Cell Counting Kit-8 (CCK-8) and transwell chamber assay. Analysis of GEO dataset concluded that EMP1 gene is down-regulated in HNSCC tumor tissues compared with normal tissues (P<0.05). There was no statistically significant difference of EMP1 gene expression between different T-stage and N-stage tumor tissues (P>0.05). The results of TMA showed that EMP1 protein expression in tumor was lower than that in normal tissue (P<0.05). Expression of EMP1 protein was not correlated with TNM stage of HNSCC. In addition, The Cal-27 overexpressed EMP1 significantly decreased cell viability and the invasion significantly reduced (P<0.05). After EMP1 overexpression ITGA3 and EPHA2 genes were significantly up-regulated, while ANXA1 gene was significantly down-regulated. Our data demonstrated that EMP1 gene down-regulation involved in the HNSCC tumorigenesis and development. It may serve as a novel biomarker for prognostic evaluation of patients with HNSCC.

Free access to ScienceDirect and Scopus

To assist you with reviewing this manuscript it is our pleasure to offer you 30 days of free access to ScienceDirect and Scopus. Your complimentary access can be accessed at any time within 6 months of the day you accept this review invitation and will ensure that you can access ScienceDirect and Scopus both from home and via your institute. Just click on the ‘Go to Scopus’ tab on your main menu.

Have questions or need assistance?

For more information on the review process, please visit the Reviewer Support site.

For further assistance, please visit our Customer Support site. Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about EVISE® via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

————————————————————

Copyright © 2017 Elsevier B.V. | Privacy Policy

Elsevier B.V., Radarweg 29, 1043 NX Amsterdam, The Netherlands, Reg. No. 33156677.

Journal of Stem Cell Research & Therapeutics (2475-5540)

Dear Dr. Anand S Srivastava,

Hope you are doing well.

At first, I sincerely apologize if am disturbing you in your hectic schedule.

We are glad to let you know that Journal of Stem Cell Research & Therapeutics (2475-5540) have successfully released the former issues in 2016.

Moreover we are running with Volume 2 issue 2 and we are in need of one article to accomplish this issue. In fact we have gone through your eminent articles in online and my desire is to fulfill the issue with your article.

Hence I humbly request you to submit your manuscript (Review/Mini review/Case Report) at the earliest. Your prompt submission will help me to release the issue in time and will impact my ranking too.

Hope you will understand us and look forward to receive your manuscript as early as possible.

Await your reply.

Best Regards,

Melissa Hawkins

Hi Dr. Anand S. Srivastava,
Greetings from Journal of Stem Cell Research

Journal of Stem Cell Research is successfully publishing quality open access articles with the support from scientists like you. We are aware of your reputation for quality of research and trustworthiness in the field of “Stem Cell Research” and that is why you have been inviting to join as an Editorial Board Member of our Journal of Stem Cell Research.

Please send us your updated CV, biography, research interest and recent passport size photo. 

Feel free to contact us for further assistance. We are ready to serve you.
We look forward for a long lasting scientific relationship with you.

Sincerely,
Rapture D
editor.jscr@opastjournals.com

Managing Editor

Overland Park, KS
US

Invitation from Journal of Clinical Research and Trial to Submit a Manuscript

Dear Anand S,

Greetings from Clinical Research and Trials (CRT) !

This is a special Request regarding manuscript contribution to our Journal. We will be glad if you can submit your manuscript along with cover letter at clinicaltrials@oatextjournals.com

We would like to inform you regarding our Annual Membership Program. Keeping in view your tremendous contribution to the scientific field, we wish to offer you free membership.

Kindly let us know your opinion in this regard. So, that we will send you more details regarding individual membership and other benefits.

Awaiting for your positive response.

Have a great day

Best Regards
Regina Mathew
Editorial Coordinator
Office Gold, building 3 Chiswick Park
Greater London, W4 5YA
United Kingdom

Dr. Anand’s Invitation from Journal of Integrative Molecular Medicine to Submit and Article to Enhance Journal Rating

Dear Doctor Srivastava,

Hope you are doing well.

Integrative Molecular Medicine (IMM) welcomes you to contribute any type of articles for Volume 4 Issue 1. Kindly submit your article by January 20th, 2017. Your scientific contribution would help in enhancing the rating of this journal.

Our journal is indexed in the following services mentioned below:

Google Scholar, German Cancer Research Center, EZB Electronic Journals Library, World cat, Zeitschriftendatenbank (ZDB), Citefactor, Road Directory, SciCurve, AS-FHJ, RefSeek. We are applied for Indexing in EBSCO, EMBASE, and CAS. We are sure that your article will enhance the impact of our journal.

https://oatext.com/IntegrativeMolecularMedicine.php#External_Databases_Indexes

Awaiting your response.

Feel free to contact us for further queries.

Best regards,

Ian White

Managing Editor for Editor-in-chief (Koji Wakame)

Integrative Molecular Medicine (IMM) (2056-6360)

Make An Enquiry

We are here to help you

Call Us +91-7043008890
WordPress Video Lightbox